TSE:MDP Medexus Pharmaceuticals (MDP) Stock Price, News & Analysis C$2.70 -0.07 (-2.53%) As of 04/25/2025 03:59 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock About Medexus Pharmaceuticals Stock (TSE:MDP) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get MDP alerts:Sign Up Key Stats Today's RangeC$2.68▼C$2.8250-Day RangeC$2.04▼C$3.0352-Week RangeC$1.50▼C$5.56Volume38,500 shsAverage Volume109,206 shsMarket CapitalizationC$60.45 millionP/E Ratio12.91Dividend YieldN/APrice TargetC$5.49Consensus RatingBuy Company OverviewMedexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery. The company's products portfolio also includes Cuvposa, a glycopyrrolate oral solution; Naproxen, a Pediapharm naproxen suspension; Otixal, ciprofloxacin and flucinolone acetonide; Trispan, a triamcinolone hexacetonide injectable suspension; and Treosulfan, a bifunctional alkylating agent for use as part of a conditioning treatment for patients undergoing allogeneic hematopoietic stem cell transplantation. In addition, it offers over the counter products comprising Nyda, a topical revolutionary treatment indicated for the eradication of head lice; Relaxa, an osmotic laxative to treat occasional constipation in adults; Oralvisc to reduce joint pain and enhance joint function in osteoarthritis of the knee; Tricovel tablets with Biogenina to reduce hair shedding due to Telogen Eflluvium; and Calcia Calcium and vitamin D products. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Toronto, Canada.Read More… Medexus Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks30th Percentile Overall ScoreMDP MarketRank™: Medexus Pharmaceuticals scored higher than 30% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingMedexus Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.29, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageMedexus Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about Medexus Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Medexus Pharmaceuticals is 12.91, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 21.68.Price to Earnings Ratio vs. SectorThe P/E ratio of Medexus Pharmaceuticals is 12.91, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 22.39.Price to Book Value per Share RatioMedexus Pharmaceuticals has a P/B Ratio of 2.00. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for MDP. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMedexus Pharmaceuticals does not currently pay a dividend.Dividend GrowthMedexus Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for MDP. News and Social Media0.0 / 5News SentimentN/A Search InterestOnly 1 people have searched for MDP on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Medexus Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.14% of the stock of Medexus Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 8.32% of the stock of Medexus Pharmaceuticals is held by institutions.Read more about Medexus Pharmaceuticals' insider trading history. Receive MDP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medexus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address MDP Stock News HeadlinesShould We Be Delighted With Medexus Pharmaceuticals Inc.'s (TSE:MDP) ROE Of 11%?April 18, 2025 | finance.yahoo.comCanadian Investment Regulatory Organization Trading Halt - MDPJanuary 29, 2025 | finance.yahoo.comTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.April 26, 2025 | Porter & Company (Ad)Canadian Investment Regulatory Organization Trade Resumption - MDPJanuary 29, 2025 | ca.finance.yahoo.comDespite the downward trend in earnings at Medexus Pharmaceuticals (TSE:MDP) the stock spikes 16%, bringing one-year gains to 48%December 25, 2024 | finance.yahoo.comShould We Be Cautious About Medexus Pharmaceuticals Inc.'s (TSE:MDP) ROE Of 7.0%?November 10, 2024 | finance.yahoo.comMedexus Pharmaceuticals Inc (TSX:MDP) Q2 2025: Everything You Need to Know Ahead of EarningsNovember 7, 2024 | finance.yahoo.comMedexus Pharmaceuticals Inc (TSX:MDP) Q2 2025 Earnings Report Preview: What To Look ForNovember 6, 2024 | finance.yahoo.comSee More Headlines MDP Stock Analysis - Frequently Asked Questions How have MDP shares performed this year? Medexus Pharmaceuticals' stock was trading at C$3.46 on January 1st, 2025. Since then, MDP shares have decreased by 22.0% and is now trading at C$2.70. View the best growth stocks for 2025 here. How do I buy shares of Medexus Pharmaceuticals? Shares of MDP stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Medexus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Medexus Pharmaceuticals investors own include AutoZone (AZO), Cisco Systems (CSCO), Facedrive (FDVRF), Intel (INTC), kneat.com (KSI), NIO (NIO) and Nanotech Security (NTS). Industry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolTSE:MDP CIKN/A Webwww.medexus.com Phone877-633-3987FaxN/AEmployees98Year FoundedN/APrice Target and Rating Average Stock Price TargetC$5.49 High Stock Price TargetC$8.25 Low Stock Price TargetC$3.45 Potential Upside/Downside+103.2%Consensus RatingBuy Rating Score (0-4)3.29 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)C$0.21 Trailing P/E Ratio12.91 Forward P/E Ratio16.53 P/E GrowthN/ANet IncomeC$3.26 million Net Margins3.25% Pretax MarginN/A Return on Equity11.07% Return on Assets4.89% Debt Debt-to-Equity Ratio120.58 Current Ratio1.01 Quick RatioN/A Sales & Book Value Annual SalesC$100.25 million Price / Sales0.60 Cash FlowN/A Price / Cash FlowN/A Book ValueC$1.35 per share Price / Book2.00Miscellaneous Outstanding Shares22,388,156Free FloatN/AMarket CapC$60.45 million OptionableNot Optionable Beta1.96 10 Stocks Set to Soar in Spring 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (TSE:MDP) was last updated on 4/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredDeepSeek’s Clear and Present DangerDeepSeek — the alleged “$5.5 million” AI project — isn’t an open-source breakthrough. It’s a Trojan horse.Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medexus Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Medexus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.